FluoGuide is a late clinical stage biotech company maximizing surgical outcome by lighting cancer up

Approximately 20 million people are diagnosed with cancer annually worldwide, and surgery remains a central component of treatment for many patients, often requiring more than one procedure. FluoGuide aims to both improve surgical precision for these patients and potentially expand treatment opportunities for patients who are currently not considered surgical candidates.

By 2030, the number of cancer-related surgical procedures worldwide is estimated to reach approximately 45 million annually, highlighting the scale of the potential opportunity for technologies that improve intraoperative tumor visualization.

FG001 (lead product candidate) is designed to light up cancer cells during surgery. By targeting uPAR, a protein highly expressed in many solid cancers, FG001 is designed to help surgeons distinguish cancer from healthy tissue in real time.FG001 is an imaging agent built on a differentiated and scalable technology platform targeting uPAR (urokinase-type plasminogen activator receptor), an intelligent target that is a tumor-associated receptor broadly expressed across all solid cancers. This provides the potential for precision targeting across multiple oncology indications.